<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2075">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04430049</url>
  </required_header>
  <id_info>
    <org_study_id>2020 HAD-Covid</org_study_id>
    <nct_id>NCT04430049</nct_id>
  </id_info>
  <brief_title>Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients</brief_title>
  <acronym>HAD-Covid</acronym>
  <official_title>Impact of the Restrictive Visiting Policy During the Covid-19 Pandemic on Anxiety, Depression and Post-traumatic Stress Disorder for Relatives of ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To limit the pandemic Covid-19 infection, the French government imposed a closure of all
      Intensive Care Unit (ICU). The family's visitations are prohibited during active Covid -19
      pandemic. This restrictive visit policy could result in an increase in symptoms of anxiety,
      depression or post-traumatic stress disorder for relatives of ICU patients. The aim of this
      study is to compare symptoms of anxiety, depression or post-traumatic stress for relatives of
      ICU patients during Covid period with those during no Covid period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational multicenter study

      Two groups are compared:

        -  restrictive visitation group. Enrollment during the application of national containment
           measures to limit Covid pandemic in France: March to June 2020

        -  open visit group. Enrollment during a no Covid period without restrictive visitation:
           March to June 2021 The primary objective is to compare the Hospital Anxiety and
           Depression Scale (HADS) for relative at 3 months after the ICU patient discharge between
           the two groups The secondary objectives are

        -  to compare the Post-Traumatic Stress Disorder (PTSD) for relative at 3 months after the
           ICU patient discharge between the two groups

        -  to compare the prevalence of significant symptoms of both anxiety and depression for
           relative at 3 months after the ICU patient discharge between the two groups

        -  to compare the prevalence of significant PTSD-related symptoms for relative at 3 months
           after the ICU patient discharge between the two groups

        -  to identify the factor associated with significant symptoms of both anxiety and
           depression

        -  to identify the factor associated with significant PTSD-related symptoms
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 22, 2020</start_date>
  <completion_date type="Anticipated">January 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety</measure>
    <time_frame>at 3 months</time_frame>
    <description>Anxiety for relative of ICU patient will be measured by the Hospital Anxiety and depression scale (HADS) assessed 3 months after the ICU discharge of patient.
HADS ranges from 0 to 42; higher scores indicate worse symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>at 3 months</time_frame>
    <description>Anxiety for relative of ICU patient will be measured by the Hospital Anxiety and depression scale (HADS) assessed 3 months after the ICU discharge of patient.
HADS ranges from 0 to 42; higher scores indicate worse symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post-traumatic stress disorder</measure>
    <time_frame>at 3 months</time_frame>
    <description>Impact of post traumatic stress disorder for relative of ICU patient will be measured with the Event scale revised (IES-R) assessed 3 months after the ICU discharge of patient.
IES-R ranges from 0 to 88; higher scores indicate worse symptoms</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Covid-19</condition>
  <condition>Family Members</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>restrictive visitation group</arm_group_label>
    <description>relatives cannot visit ICU patient during Covid pandemic period in France</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open visitation group</arm_group_label>
    <description>relatives can visit ICU patient during no Covid period in France</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Covid ICU containment measures</intervention_name>
    <description>The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU</description>
    <arm_group_label>restrictive visitation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Relative of patient who was admitted in ICU and treated with mechanical ventilation or
        non-invasive ventilation or high flow oxygen or amine administration during 24hours at
        least.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relative of patient who was admitted in ICU and treated with mechanical ventilation or
             non-invasive ventilation or high flow oxygen or amine administration during 24hours at
             least.

        Exclusion Criteria:

          -  Relative who declines the enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>+33473754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital, Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre</last_name>
      <phone>0373754963</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre Lautrette, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Gillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Médard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russel Chabanne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Cayot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Futier, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Etienne Bazin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Aurillac</name>
      <address>
        <city>Aurillac</city>
        <zip>15000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Marie-Hélène Hausermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06150</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Pierre-Marie Bertrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Nathanael Einsemann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le Puy-en-Velay</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christophe Leroy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hopistal, Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Moulins</name>
      <address>
        <city>Moulins</city>
        <zip>03000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Luc Jarrige, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Périgueux</name>
      <address>
        <city>Périgueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Edouard Soum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Arnaud Delahaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Vichy</name>
      <address>
        <city>Vichy</city>
        <zip>03200</zip>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Ramin Ravan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Family</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Post-traumatic stress disorder</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Visitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

